Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

PH3 R-CHOP +/- Acalab Tx Naive DLBCL

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Disease Types: Lymphomas,&nbs

Available at: {clinical_trial_location backspace="7"}PH3 R-CHOP +/- Acalab Tx Naive DLBCL, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}